{"doi":"10.1055/s-2006-945953","title":"SEIZURE RISK IN PATIENTS WITH ADHD TREATED WITH ATOMOXETINE","abstract":null,"journal":"Neuropediatrics","year":2006,"id":596437,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1527551,"name":"KE Chilcott","orcid":null,"position":1,"is_corresponding":false},{"id":1527555,"name":"L Jin","orcid":null,"position":2,"is_corresponding":false},{"id":1527558,"name":"T Edison","orcid":null,"position":3,"is_corresponding":false},{"id":188646,"name":"S Zhang","orcid":null,"position":4,"is_corresponding":false},{"id":1527562,"name":"ME Bangs","orcid":null,"position":5,"is_corresponding":false},{"id":1527564,"name":"HA Read","orcid":null,"position":6,"is_corresponding":false},{"id":1527565,"name":"DD Ruff","orcid":null,"position":7,"is_corresponding":false},{"id":1527567,"name":"AJ Allen","orcid":null,"position":8,"is_corresponding":false},{"id":1527568,"name":"D Dunn","orcid":null,"position":9,"is_corresponding":false},{"id":1527547,"name":"JF Wernicke","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"SEIZURE RISK IN PATIENTS WITH ADHD TREATED WITH ATOMOXETINE","abstract":"Objectives: Atomoxetine was approved in the US for treatment of ADHD in November 2002. As stimulants are often thought to lower the seizure threshold, it is important to consider the relationship between atomoxetine and seizures, especially given the evidence that patients with ADHD may be at increased risk of seizures.","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W2331700713","authors":[],"funders":[],"total_grants":0,"fwci":0.9639,"citation_percentile":0.74112158,"influential_citations":0,"citation_trend":[{"year":2018,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.thieme-connect.de/DOI/DOI?10.1055/s-2006-945953","host_type":"publisher"},{"url":"https://doi.org/10.1055/s-2006-945953","host_type":"journal"}],"fields_of_study":["Attention Deficit Hyperactivity Disorder"],"mesh_terms":[],"keywords":["Atomoxetine","Medicine","Atomoxetine hydrochloride","Epilepsy","Psychiatry","Attention deficit hyperactivity disorder","Pediatrics","Methylphenidate"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T10:14:58.181083Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}